Literature DB >> 33638106

Long-term outcomes of single-incision versus multiport laparoscopic colectomy for colon cancer: results of a propensity score-based analysis.

Yozo Suzuki1,2, Mitsuyoshi Tei3, Masaki Wakasugi3, Yujiro Nakahara4, Atsushi Naito4, Manabu Mikamori4, Kenta Furukawa4, Masahisa Ohtsuka4, Jeong Ho Moon4, Mitsunobu Imasato4, Tadafumi Asaoka4, Kentaro Kishi4, Hiroki Akamatsu4.   

Abstract

BACKGROUND: Long-term outcomes of single-incision laparoscopic colectomy (SILC) for colon cancer (CC), as practiced in real-world settings, especially in relation to disease stage, have not been established. We examined, retrospectively, both short- and long-term outcomes of SILC versus those of multiport laparoscopic colectomy (MPLC) performed for CC in a propensity-score-matched cohort.
METHODS: The study involved 263 patient pairs matched 1:1 from among 691 patients who, between January 2008 and May 2014, underwent either SILC or MPLC for a primary solitary CC at our hospital. Short-term and long-term operative outcomes were compared between the two groups.
RESULTS: Operation time was the only surgical outcome that varied significantly between the two groups (p = 0.0004). Overall 5-year cancer-specific survival (CSS) in the SILC group was 93.7 (95% CI 89.6-96.2)%, and CSS per pathological stage (I, II and III) was 98.5 (90.0-99.8)%, 96.0 (88.2-98.7)%, and 88.3 (79.6-93.6)%, respectively, whereas overall 5-year CSS in the MPLC group was 93.3 (89.4-95.9)%, and CSS per pathological stage was 100%, 95.4 (88.3-98.3)%, and 84.1 (74.1-90.8)% (p = 0.5278, 0.2679, 0.7666, and 0.9073), respectively. Overall 3-year disease-free survival (DFS) in the SILC group was 94.0 (90.2-96.4)%, and 3-year DFS per pathological stage was 98.6 (90.4-99.8)%, 90.1 (81.4-95.0)%, and 79.0 (69.4-86.2)%, respectively, whereas overall 3-year DFS in the MPLC group was 93.2 (89.4-95.7)%, and 3-year DFS per pathological disease stage was 100%, 94.5 (87.4-97.7)% and 75.5 (64.7-83.8)% (p = 0.2829, 0.7401, 0.4335 and 0.8518), respectively. Thus, oncological outcomes did not differ significantly between groups. Incisional hernia occurred in 21 (8.0%) SILC group patients and 17 (6.5%) MPLC group patients, without a significant between-group difference (p = 0.6139).
CONCLUSION: Our data indicate that perioperative and oncological outcomes of SILC performed for CC are comparable to those of MPLC performed for CC.
© 2021. The Author(s), under exclusive licence to Springer Science+Business Media, LLC part of Springer Nature.

Entities:  

Keywords:  Colon cancer; Long-term outcome; Single-incision laparoscopic surgery

Mesh:

Year:  2021        PMID: 33638106     DOI: 10.1007/s00464-021-08367-4

Source DB:  PubMed          Journal:  Surg Endosc        ISSN: 0930-2794            Impact factor:   4.584


  43 in total

Review 1.  Feasibility and safety of single-incision laparoscopic colectomy: a systematic review.

Authors:  Tomoki Makino; Jeffrey W Milsom; Sang W Lee
Journal:  Ann Surg       Date:  2012-04       Impact factor: 12.969

2.  Short-term surgical outcomes from a randomized controlled trial to evaluate laparoscopic and open D3 dissection for stage II/III colon cancer: Japan Clinical Oncology Group Study JCOG 0404.

Authors:  Seiichiro Yamamoto; Masafumi Inomata; Hiroshi Katayama; Junki Mizusawa; Tsuyoshi Etoh; Fumio Konishi; Kenichi Sugihara; Masahiko Watanabe; Yoshihiro Moriya; Seigo Kitano
Journal:  Ann Surg       Date:  2014-07       Impact factor: 12.969

Review 3.  Systematic review with meta-analysis of studies comparing single-incision laparoscopic colectomy and multiport laparoscopic colectomy.

Authors:  Mauro Podda; Alessandra Saba; Federica Porru; Adolfo Pisanu
Journal:  Surg Endosc       Date:  2016-02-23       Impact factor: 4.584

4.  Survival after laparoscopic surgery versus open surgery for colon cancer: long-term outcome of a randomised clinical trial.

Authors:  Mark Buunen; Ruben Veldkamp; Wim C J Hop; Esther Kuhry; Johannes Jeekel; Eva Haglind; Lars Påhlman; Miguel A Cuesta; Simon Msika; Mario Morino; Antonio Lacy; Hendrik J Bonjer
Journal:  Lancet Oncol       Date:  2008-12-13       Impact factor: 41.316

Review 5.  Meta-analysis of single-port versus conventional laparoscopic cholecystectomy comparing body image and cosmesis.

Authors:  R Haueter; T Schütz; D A Raptis; P-A Clavien; M Zuber
Journal:  Br J Surg       Date:  2017-06-01       Impact factor: 6.939

6.  Laparoscopy-assisted colectomy versus open colectomy for treatment of non-metastatic colon cancer: a randomised trial.

Authors:  Antonio M Lacy; Juan C García-Valdecasas; Salvadora Delgado; Antoni Castells; Pilar Taurá; Josep M Piqué; Josep Visa
Journal:  Lancet       Date:  2002-06-29       Impact factor: 79.321

7.  A comparison of laparoscopically assisted and open colectomy for colon cancer.

Authors:  Heidi Nelson; Daniel J Sargent; H Sam Wieand; James Fleshman; Mehran Anvari; Steven J Stryker; Robert W Beart; Michael Hellinger; Richard Flanagan; Walter Peters; David Ota
Journal:  N Engl J Med       Date:  2004-05-13       Impact factor: 91.245

Review 8.  Single-incision versus three-port laparoscopic appendectomy for acute appendicitis: systematic review and meta-analysis of randomized controlled trials.

Authors:  A-Man Xu; Lei Huang; Tuan-Jie Li
Journal:  Surg Endosc       Date:  2014-08-09       Impact factor: 4.584

9.  Short-term outcomes of the Australasian randomized clinical study comparing laparoscopic and conventional open surgical treatments for colon cancer: the ALCCaS trial.

Authors:  Peter J Hewett; Randall A Allardyce; Philip F Bagshaw; Christopher M Frampton; Francis A Frizelle; Nicholas A Rieger; J Shona Smith; Michael J Solomon; Jacqueline H Stephens; Andrew R L Stevenson
Journal:  Ann Surg       Date:  2008-11       Impact factor: 12.969

Review 10.  Comparison of laparoendoscopic single-site versus conventional multiple-port laparoscopic herniorrhaphy: a systemic review and meta-analysis.

Authors:  Chi-Wen Lo; Stephen Shei-Dei Yang; Yao-Chou Tsai; Cheng-Hsing Hsieh; Shang-Jen Chang
Journal:  Hernia       Date:  2015-12-08       Impact factor: 4.739

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.